Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
To demonstrate the superiority of QVA149 27.5/12.5 μg twice a day as compared to fluticasone/salmeterol 250/50 μg twice a day in COPD patients with moderate to severe airflow limitation in terms of standardized FEV1 AUC0-12h at Week 12.
Critère d'inclusion
- COPD patients with moderate to severe airflow limitation